Payers and access bottlenecks
- Coverage gaps and limited real‑world evidence are shaping payer decisions and slowing patient access to GLP‑1s. (ajmc.com) - Eli Lilly CEO David Ricks estimated weight‑loss drugs may ultimately reach about 50% of potential users at peak. (pharma.economictimes.indiatimes.com) - Insurer selectivity and step‑therapy policies could determine which patients actually receive these therapies. ( )
GLP-1 drugs can produce large weight loss, but insurance rules are deciding who actually gets them. David Ricks, Eli Lilly’s chief executive, said on April 17 that these medicines may reach only about half of eligible patients at peak. (finance.yahoo.com) Ricks said just 1 in 10 overweight or obese people are using GLP-1s today, and he put the long-run ceiling at 40% to 50%, comparing them with statins. He also said Lilly is treating about 21 million to 22 million people now and would need roughly a 20-fold production increase to serve a 500 million-person market. (finance.yahoo.com) The bottleneck is not only factory output. Ben Urick, a University of North Carolina pharmacy professor, said in an April 2026 interview with The American Journal of Managed Care that coverage gaps and limited real-world evidence are shaping payer decisions on obesity drugs. (ajmc.com) GLP-1 stands for glucagon-like peptide-1, a hormone pathway these drugs mimic to lower blood sugar and reduce appetite. In the United States, the same drug class is often covered for type 2 diabetes, heart disease, or sleep apnea, while coverage for obesity alone remains narrower. (ncsl.org (kff.org) That split shows up across public and private insurance. KFF said on January 30 that Medicare covers GLP-1s for type 2 diabetes, cardiovascular disease, and sleep apnea, but federal law still bars Medicare coverage of drugs used solely for weight loss. (kff.org) States are uneven too. The National Conference of State Legislatures said on March 23 that, as of January 2026, 13 state Medicaid programs covered GLP-1s for obesity treatment, while state employee plans and Medicaid programs varied widely in how they handled obesity drugs. (ncsl.org) Employers have been expanding coverage, but selectively. KFF said one in five firms with 200 or more workers covered GLP-1 drugs for weight loss in 2025, and the share rose to 43% among firms with 5,000 or more workers, up from 28% in 2024. (healthsystemtracker.org (kff.org) Even when plans cover the drugs, employers and insurers are tightening the gate. KFF said many employers were considering scaling back coverage or adding stronger requirements, and state and private plans commonly use prior authorization and other cost controls that can change over time. (kff.org) (ncsl.org) Cost sits under nearly every coverage decision. The National Conference of State Legislatures said average monthly list prices run from $936 to $1,023, and Reuters reported self-pay prices for Lilly’s lowest-dose GLP-1 pills and injectables ranging from $149 to $349 per month. (ncsl.org) (finance.yahoo.com) Use is already climbing where coverage exists. KFF said 2 million Medicare Part D enrollees used Ozempic in 2024, up from fewer than 150,000 in 2019, and nearly 1 million took Mounjaro in 2024, up from 54,000 in 2022. (kff.org) The next fight is less about whether GLP-1s work than about which diagnosis, which plan, and which paperwork unlocks them. Ricks said “it’s never going to be a hundred,” and payers are making sure the path to that ceiling stays narrow. (finance.yahoo.com)
